Moderna Inc (NASDAQ:MRNA) reported a collaboration with Chiesi Group to discover and develop mRNA for pulmonary arterial hypertension. The company also announced a collaboration with Vertex to treat cystic fibrosis using gene editing.
The Cambridge, Mass.-based company also announced progress across its portfolio of pipeline assets being presented at the Company’s annual R&D Day today.
Said CEO Stephane Bancel, "The Moderna team has made significant progress since our last R&D Day 12 months ago. The pipeline has matured with our COVID-19 vaccine in a Phase 3 study and four candidates in Phase 2 studies. We are actively preparing for a potential commercial launch of mRNA-1273, our COVID-19 vaccine, and we continue to expand the breadth of Moderna’s platform.
"We are announcing that we are increasing our investment in vaccines and we will develop a seasonal flu vaccine given the unmet need for highly effective vaccines. In our systemic secreted & cell surface therapeutics core modality, we are sharing positive interim data for repeat dosing of our systemic mRNA therapeutic against chikungunya, which is important progress for our therapeutics modalities, particularly in rare diseases."
Moderna currently has 23 mRNA development candidates in its portfolio with 14 in clinical studies. Across Moderna’s pipeline, more than 27,000 healthy volunteers and patients have been enrolled in clinical studies including the Phase 3 study of mRNA-1273.
Shares gained 14 cents to $68.82.
